Following the Medtronic recall of their Sprint Fidelis heart leads the FDA released a statement covering the background of the Medtronic leads and recommendations.
Neither the FDA, Medtronic, nor representatives of the Heart Rhythm Society, recommend the routine surgical removal of a fractured lead because removal carries risks. Instead, physicians should weigh the benefits and risks of either continuing to use the lead with careful monitoring or capping the lead so it is no longer useable and implanting a different model. The following Medtronic statement accompanied their letter to physicians on October 15, 2007.
October 2007
This attachment accompanies Medtronic’s physician letter dated October 15, 2007 and provides information concerning risks inherent in lead extractions.
Medtronic’s Independent Physician Quality Panel believes it is inappropriate to prophylactically remove Sprint Fidelis® leads except in unusual individual patient circumstances. We support this position.
Extraction of chronic leads entails substantial risks of patient morbidity and mortality. Reported complications1 include: lead breakage and migration; avulsion of veins, myocardium or the tricuspid valve; tears of the myocardium or veins; hemothorax, tamponade, perforation, emergency cardiothoracic surgery, pulmonary emboli, and death.
In evaluating whether to extract any cardiac lead, physicians must weigh the risks and benefits of leaving the lead in place in comparison to those of removal. Major complications from lead extraction, defined as death or the requirement of a significant surgical intervention, have been reported in multiple series to be in the range of 1.4-7.3% of patients.2,3 Factors reported to increase the risk of major complications include: duration of implant, female gender, and large removal sheaths.4,5
Medtronic Sprint Fidelis performance data indicate all-cause lead survival of 97.7% at 30 months (SLS, Medtronic CareLink® Network analysis). High voltage conductor fractures could result in the inability to deliver defibrillation therapy. Anode or cathode conductor fractures at either of the primary fracture locations may present clinically as increased impedance, oversensing, increased interval counts, multiple inappropriate shocks, and/or loss of pacing output. Utilization of the patient management recommendations will increase the likelihood that a fracture will be detected by Patient AlertTM and/or Medtronic CareAlert® notifications (see Appendix C) and decrease the likelihood of inappropriate therapies. Based on current information, we have identified five patient deaths in which a Sprint Fidelis lead fracture may have been a possible or likely contributing factor. (0.0018% of approximately 268,000 implants worldwide). By comparison, the risk of major complications (cardiac surgery or death) with lead extraction is 1.4-7.3%.
It has been reported that limited physician experience (< 50 procedures) may significantly increase the risk of complications from extraction.6 For this reason, Medtronic’s Independent Physician Quality Panel recommends that if a lead requires removal, the procedure be performed by a physician with extensive lead extraction experience.
These recommendations are consistent with the HRS Policy Statement on recommendations for extraction of chronically implanted leads.7
References
1. Byrd CL, Wilkoff BL, in Clinical Cardiac Pacing and Defibrillation, Ellenbogen, Kay and Wilkoff editors. WB Saunders 2000, Techniques and Devices for Extraction of Pacemaker and Implantable Cardioverter Defibrillator Leads: 695-709.
2. Byrd et al, Intravascular extraction of problematic or infected permanent pacemaker leads: 1994-1996. U.S. Extraction Database, MED Institute. PACE. 1999;22(9):1349-1357.
3. Bracke et al, Lead extraction for device related infections: a single-centre experience. Europace May 2004; 6(3):243-247.
4. Byrd et al. PACE. 1999;22(9):1349-1357.
5. Kennergren et al, Laser-assisted lead extraction: the European experience. Europace. August 2007; 9(8):651-656.
6. Byrd et al. PACE. 1999;22(9):1349-1357.
7. NASPE Policy Statement: Recommendations for Extraction of Chronically Implanted Transvenous Pacing and Defibrillator Leads: Indications, Facilities, Training. Love CJ, Wilkoff BL, et al. PACE. 2000; 23, 544-551.
If you have questions or concerns, please contact your Medtronic Representative or Medtronic Technical Services at 1-800-723-4636 (US).
If you or a loved one has been injured by a defective Medtronic defibrillator lead please contact us for a free consultation and case review. A Medtronic recall class action attorney can go over your legal rights and options and evaluate any potential claims you may have. You may be entitled to compensation and we can help.
We are a law firm dedicated to helping those injured by Medtronic Sprint Fidelis Defibrillator Lead.
Medtronic Recall Lawsuit
U.S. Food & Drug Administration Statement On Medtronic Sprint Fidelis Defibrillator
Medtronic Suspends Sprint Fidelis Defibrillation Leads (PDF)
U.S. FDA Class 1 Recall Report
If you or a loved one have been injured by the Medtronic Sprint Fidelis lead please contact us immediately. You may be entitled to compensation.
If you or someone you know has received a Medtronic 6931 defibrillator lead you may have important legal rights. Many heart patients have experienced a lead fracture which can cause painful and sometimes life-threatening shocks to the heart or alternatively not provide a shock when needed. We are currently representing patients who have defective Medtronic [...]
If you or someone you know has received a Sprint Fidelis defibrillator lead 6949 you may have important legal rights. Many patients have experienced a lead fracture which can cause painful and sometimes life-threatening shocks to the heart or alternatively not provide a shock when needed. We are currently representing patients who have a defective [...]
On October 15, 2007 a Medtronic recall was issued due to reports of at least five patient deaths linked with defective defibrillator leads. The heart leads are susceptible to fracture which can then cause the defibrillator to deliver unnecessary shocks or not operate at all. Following the recall no more Sprint Fidelis leads were sold [...]
The Minneapolis Heart Institute conducted a study of the Medtronic Sprint Fidelis 6949 lead and determined that the lead had a greater failure rate compared to the Quattro lead. In October 2007 Medtronic announced a recall of Sprint Fidelis lead 6949 along with leads 6948, 6930 and 6931.
Medtronic Lead Failure
Minneapolis Heart Institute Foundation Study
Early failure [...]
On September 4, 2008 the FDA released a News Alert regarding a software update from Medtronic that is supposed to help detect Sprint Fidelis lead fractures. Approximately 268,000 Sprint Fidelis lead have been implanted in patients worldwide. The Medtronic recall of heart leads included four Sprint Fidelis models: 6930, 6931, 6948 and 6949.
Recalls Sprint Fidelis
FDA [...]